Special Issue

Zebrafish Models for Development and Disease 3.0

Message from the Guest Editors

The zebrafish is an important model organism, which is used to study normal development, genetic diseases and influences of environmental toxins. Advanced, cutting edge technologies like gene editing, next-generation DNA sequencing and transgenic techniques produced experimental approaches in the zebrafish model that address mechanisms of development and vertebrate evolution. Increasingly, the zebrafish is being used to explore the neural structures that control behavior, which have applications for neurology, psychology and psychiatry. The zebrafish has advantages for neurobiology because the brain is simpler than that of mammals, but the structures, neurochemistry and behaviors have a high degree of conservation relative to other vertebrates. This call for papers invites contributions of original research and reviews for this Special Issue of *Biomedicines* entitled "Zebrafish Models in Development and Disease". The Special Issue will explore the diverse capabilities of the zebrafish model that can be applied to biological and preclinical research.

Guest Editors

Prof. Dr. James A. Marrs

Department of Biology, Indiana University Indianapolis, Indianapolis, IN, USA

Dr. Swapnalee Sarmah

Department of Biology, Indiana University-Purdue University Indianapolis, Indianapolis, IN, USA

Deadline for manuscript submissions

closed (30 September 2022)

Biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).